Recent reports from a phase I clinical trial reveal that the HER3 ADC (patritumab deruxtecan, U3-1402, or HER3-DXd) shows a good safety profile and promising clinical benefit in EGFR-TKI resistant NSCLC patients [75]. Here, ERBB3 is linked to non-small cell lung carcinoma.